drugset / Trial / NCT00964262
A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide
RandomizedSingle-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of SR exenatide (PT302) in healthy subjects.
Timeline
- Start
- 2009-08
- Primary completion
- 2010-10
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exenatide | Peptide | 0.5 mg | Subcutaneous |
| Subject | Exenatide | Peptide | 1 mg | Subcutaneous |
| Subject | Exenatide | Peptide | 2 mg | Subcutaneous |
| Subject | Exenatide | Peptide | 4 mg | Subcutaneous |